Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Comorbid Anxiety Symptoms.

Trial Profile

Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Comorbid Anxiety Symptoms.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jan 2012

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Affective disorders; Anxiety disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jan 2012 Actual patient number is 39 according to ClinicalTrials.gov.
    • 04 Jan 2012 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 04 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top